MedPath

Clinical Applicability of pCASL as a Substitute for FDG-PET in MCI and SCD Patients

Recruiting
Conditions
Mild Cognitive Impairment
Subjective Cognitive Decline
Registration Number
NCT05756270
Lead Sponsor
University of Milano Bicocca
Brief Summary

The goal of this observational study is to compare cerebral perfusion patterns with pseudo-continuous arterial spin labeling (pCASL) and brain metabolism patterns with fluorodeoxyglucose-position emission tomography (FDG-PET) in patients with mild cognitive impairment (MCI) and subjective cognitive decline (SCD). The main questions it aims to answer are:

* Do pCASL sequences identify hypoperfusion patterns that correlate well with FDG-PET hypometabolic patterns?

* Are there differences in this correlation in terms of cerebrospinal fluid (CSF) profiles?

* Can hypoperfusion patterns in pCASL predict conversion to dementia? Participants will undergo brain 3 Tesla magnetic resonance imaging (MRI), FDG-PET, lumbal puncture and blood collection to analyze amyloid beta and tau, yearly detailed neuropsychological tests for three years.

Detailed Description

Not available

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
150
Inclusion Criteria
  • Patients with mild cognitive impairment or subjective cognitive decline according to established criteria
  • Clinical Dementia Rating scale of 0 or 0.5
  • Signed informed consent before study entry
Exclusion Criteria
  • Contraindication to brain MRI, FDG-PET or lumbar puncture
  • Secondary causes of cognitive decline
  • Known major neurological or psychiatric comorbidities
  • History of substance or alcohol abuse
  • Known causes of cerebral brain perfusion alterations
  • Enrollment in anti-amyloid or anti-tau drugs trials

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Correlation between brain hypoperfusion and brain hypometabolism at baselineBaseline

The investigators will correlate cerebral perfusion indices and standardized uptake value ratios (SUVr) ratios for each pre-specified region of interest (ROI) within statistical parametric mapping (SPM) Automatic Anatomic Labeling (AAL), after coregistration on T1 sequences

Correlation between brain hypoperfusion and brain hypometabolism at baseline according to CSF profileBaseline

The investigators will correlate cerebral perfusion indices and SUVr for each pre-specified ROI (region of interest) within SPM Automatic Anatomic Labeling (AAL), after coregistration on T1 sequences. This analysis will be done within subgroups according to CSF status according to amyloid beta, phosphorylated tau and total tau.

Secondary Outcome Measures
NameTimeMethod
Correlations between brain hypoperfusion and CSF and blood biomarkersBaseline

The investigators will perform correlations between brain hypoperfusion indices for each ROI and values of CSF and blood amyloid beta, phosphorylated tau and total tau

Correlations between brain hypoperfusion and neuropsychological testsBaseline, 1 year, 2 years

The investigators will perform correlations between brain hypoperfusion indices for each ROI and various neuropsychological (NPS) test scores

Predictive properties of brain hypoperfusion and brain hypometabolism for conversion to dementia1 year, 2 years

The investigators will analyze correlations between each ROI hypoperfusion and conversion to dementia rates within the prespecified time frame. In case of significant associations, a receiver operating characteristic curve (ROC) analysis will be carried out to individuate optimal cut-offs for cerebral blood flow indices and SUVr to predict conversion of dementia

Differences among brain hypoperfusion patterns according to amyloid and tau statusBaseline

The investigators will analyze differences in brain perfusion indices for each ROI among patients wit amyloid positive status, amyloid and tau negative status, and amyloid negative - tau positive status

Trial Locations

Locations (1)

Fondazione IRCCS San Gerardo dei Tintori

🇮🇹

Monza, MB, Italy

© Copyright 2025. All Rights Reserved by MedPath